This quarter
the fda's cagrisema clock is running — the tirzepatide head-to-head left a question mark
The FDA has a Q4 2026 milestone on its schedule for CagriSema, Novo Nordisk's fixed-dose combination of cagrilintide and semaglutide. [Novo Nordisk filed the NDA in December 2025](https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html) for weight management in adults with obesity or overweight, and the company's own financial filings explicitly list a US decision milestone for Q4 2026. We are entering that quarter. The clinical story that made the NDA complicated arrived earlier this year: REDEFINE-4, a head-to-head trial that ran CagriSema against tirzepatide 15mg. CagriSema produced 23% mean body weight reduction at 84 weeks — an impressive absolute number by any previous standard in obesity pharmacology. It was not enough. The trial was designed to demonstrate noninferiority against tirzepatide and missed the statistical threshold. Tirzepatide produced more weight loss. Novo Nordisk did not pull the NDA. The FDA is still reviewing. [The company confirmed its regulatory plans following the REIMAGINE 2 results in February 2026](https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916481), and the Q4 decision window is now the clock everyone in obesity pharmacology is watching. The peptide at the center of that combination is cagrilintide, and it is worth understanding on its own terms before the verdict lands.
The actual molecule
cagrilintide is an amylin analog — the satiety signal glp-1 drugs don't carry
Cagrilintide works through a different hormone pathway than every GLP-1 receptor agonist in the obesity drug market. It is a long-acting synthetic analog of amylin — the peptide hormone the pancreas co-secretes alongside insulin in response to a meal. Amylin signals meal termination through brainstem circuits in the area postrema and nucleus tractus solitarius, slows gastric emptying, and suppresses postprandial glucagon secretion. These are complementary, not redundant, mechanisms relative to what GLP-1 receptor activation produces. That biological distinction is the entire pharmacological rationale for combining cagrilintide and semaglutide in a single injection: two distinct satiety pathways operating simultaneously from one weekly dose. Pramlintide, the approved amylin analog used in insulin-dependent diabetes management, is the earlier proof that amylin receptor pharmacology translates from endogenous hormone to synthetic drug — it requires multiple daily injections, which cagrilintide was engineered to avoid. [The PubMed literature on cagrilintide](https://pubmed.ncbi.nlm.nih.gov/?term=Cagrilintide) covers the pharmacodynamic rationale, the REDEFINE clinical program, and the dose-response relationship across populations. The combination design is not marketing; it is the mechanism.
The next-wave pitch
the headline is 'more than ozempic' — the redefine-4 data requires a qualifier
The shorthand cagrilintide has received in obesity coverage is consistent: it produces more weight loss than semaglutide, it works through a different biology, and it is the drug that comes after Ozempic. All three are accurate with qualifiers that frequently get dropped. More weight loss than semaglutide: true, in the REDEFINE trials where the comparison was against placebo or semaglutide alone. Different biology: correct, which is exactly why the combination is designed the way it is. The post-Ozempic framing depends heavily on what the FDA decides in Q4 2026 and how prescribers and payers respond to data that shows 22.7% weight loss in obesity trials but does not establish superiority to tirzepatide in head-to-head design. The post-Ozempic narrative is not wrong — it is operating at a different level of resolution than the clinical record. Cagrilintide is a real compound with real Phase 3 data. What it is not, yet, is an approved drug with a proven edge over every currently available option.
What the data says
22.7% in the obesity trial, 15.7% with type 2 diabetes, and a head-to-head against tirzepatide that didn't clear the bar
The REDEFINE program provides the clinical backbone for the NDA. REDEFINE 1, in adults with obesity or overweight without diabetes, tested CagriSema at 2.4mg cagrilintide plus 2.4mg semaglutide and found approximately 22.7% mean body weight reduction at 68 weeks versus 2.3% placebo — a separation that would have been considered extraordinary in obesity pharmacology a decade ago. REDEFINE 2, in the same population with type 2 diabetes, produced 15.7% weight loss. [REIMAGINE 2 results reported in February 2026](https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916481) ran CagriSema against semaglutide alone in type 2 diabetes and found superior weight loss — 14.2% versus 10.2% — and superior HbA1c reduction of 1.91 percentage points versus 1.76. That is a meaningful margin against semaglutide. REDEFINE-4, which ran CagriSema against tirzepatide 15mg, produced 23% weight loss at 84 weeks and did not demonstrate statistical noninferiority. The gastrointestinal adverse-event profile across trials — nausea, vomiting, constipation, mostly mild to moderate and decreasing with continued dosing — tracks the GLP-1 class pattern. [Active registrations on ClinicalTrials.gov](https://clinicaltrials.gov/search?term=Cagrilintide) show Novo Nordisk's program extending into new disease contexts since the pivotal data readout.
Early human — PeptideFactCheck stance
strong phase 3 numbers, an unresolved head-to-head, and a verdict window opening now
PeptideFactCheck rates cagrilintide Early human: interesting enough to watch, too early for broad certainty. The REDEFINE program is serious Phase 3 clinical work, and an FDA approval this quarter would mark a real milestone — the first approved injectable combination of GLP-1 and amylin receptor agonism for weight management. That milestone would be significant regardless of what REDEFINE-4 showed. What REDEFINE-4 showed is also real: tirzepatide produced more weight loss in that head-to-head, and the data will be part of any complete labeling conversation the FDA has with Novo Nordisk before a decision lands. The Early human designation reflects where the evidence sits today — substantial Phase 3 data, no approved label yet, and a head-to-head result that leaves the question of comparative effectiveness genuinely open. An approval does not retroactively change the tirzepatide comparison. A rejection or delay does not erase the 22.7% weight loss number. Both data points will matter to anyone watching this space. The FDA's [postmarket drug safety surveillance for this class](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) documents the agency's ongoing attention to GLP-1 adjacent pharmacology. Source trail before certainty.
Editorial boundary
What this page will not do
It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.